Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

Pemafibrate is under clinical development by Kowa and currently in Phase II for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). According to GlobalData, Phase II drugs for Primary Biliary ...

Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase III for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). According to GlobalData, Phase III drugs for ...

Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury, cholestasis and ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

These include different types of cholangitis (inflammation of the bile ducts), human immunodeficiency virus (HIV), and primary biliary cirrhosis (a chronic liver disease). In addition to taking ...

Primary biliary cirrhosis (PBC) is a chronic ... and primary sclerosing cholangitis (PSC). The most frequent ANA patterns in PBC sera are the 'speckled' (Figure 1), the multiple nuclear dots ...

GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver disease primary biliary cholangitis (PBC). Interim results from the ...

For primary biliary cirrhosis, ursodeoxycholic acid is safe ... For primary sclerosing cholangitis there are no established immunomodulatory therapies, but medical, endoscopic, and surgical ...

Background—Fatigue is a frequent and debilitating symptom in patients with primary biliary cirrhosis (PBC). Aims—To study fatigue in relation to sleep, depression, and liver disease severity.